These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34974510)

  • 1. One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema.
    Sheu SJ; Yang CH; Lai CC; Wu PC; Chen SJ
    J Chin Med Assoc; 2022 Feb; 85(2):246-251. PubMed ID: 34974510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study.
    Garweg JG; Stefanickova J; Hoyng C; Schmelter T; Niesen T; Sowade O; Sivaprasad S;
    Ophthalmol Retina; 2019 Jul; 3(7):567-575. PubMed ID: 31080168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial.
    Hirano T; Toriyama Y; Takamura Y; Sugimoto M; Nagaoka T; Sugiura Y; Okamoto F; Saito M; Noda K; Yoshida S; Ishibazawa A; Sawada O; Murata T
    Jpn J Ophthalmol; 2021 May; 65(3):354-362. PubMed ID: 33559843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective trial of treat-and-extend regimen with aflibercept for branch retinal vein occlusion: 1-year results of the PLATON trial.
    Park DG; Jeong WJ; Park JM; Kim JY; Ji YS; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2021 Oct; 259(10):2879-2886. PubMed ID: 33914158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
    Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EFFECT OF BASELINE CENTRAL RETINAL THICKNESS ON THE RESULTS OF TREATMENT OF DIABETIC MACULAR EDEMA WITH AFLIBERCEPT: REAL-LIFE EVIDENCE IN THE CZECH REPUBLIC.
    Němčanský J; Stepanov A; Veith M; Koubek M; Kopecký A; Němčanská S; Beran D; Studnička J
    Cesk Slov Oftalmol; 2022; 78(2):64-70. PubMed ID: 35477246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal aflibercept for diabetic macular edema.
    Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
    Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema.
    Hirano T; Toriyama Y; Takamura Y; Sugimoto M; Nagaoka T; Sugiura Y; Okamoto F; Saito M; Noda K; Yoshida S; Ishibazawa A; Sawada O; Murata T
    Sci Rep; 2021 Feb; 11(1):4488. PubMed ID: 33627712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
    Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
    JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
    Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
    Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Chang AA; Li H; Broadhead GK; Hong T; Schlub TE; Wijeyakumar W; Zhu M
    Ophthalmology; 2014 Jan; 121(1):188-192. PubMed ID: 24144450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes.
    Mieno H; Yoneda K; Terao N; Yoshii K; Kojima K; Nagata K; Sotozono C
    Korean J Ophthalmol; 2020 Aug; 34(4):290-296. PubMed ID: 32783421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
    Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
    Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
    Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
    Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.